Losartan effect on creatinine
Pro Research Analysisby 
Searched over 200M research papers
Losartan's Effect on Creatinine Levels: A Comprehensive Review
Introduction to Losartan and Creatinine
Losartan is a selective angiotensin II receptor antagonist commonly used to manage hypertension and protect renal function, particularly in patients with diabetes and nephropathy. One of the critical markers for kidney function is serum creatinine, and understanding how losartan affects creatinine levels is essential for optimizing treatment strategies.
Losartan and Reduction in Serum Creatinine Doubling
Several studies have demonstrated that losartan significantly reduces the incidence of a doubling of serum creatinine levels. In the RENAAL study, losartan was shown to reduce the incidence of doubling serum creatinine by 25% compared to placebo (p=0.006) 12. This reduction is crucial as it indicates a slower progression of renal impairment in patients treated with losartan.
Losartan's Impact on End-Stage Renal Disease (ESRD)
Losartan not only affects serum creatinine levels but also has a significant impact on the progression to end-stage renal disease (ESRD). The RENAAL study reported a 28% reduction in the incidence of ESRD in patients treated with losartan compared to those receiving a placebo (p=0.002) 12. This finding underscores the protective role of losartan in preserving kidney function over time.
Comparative Studies with Other Antihypertensive Agents
When compared to other antihypertensive agents like enalapril, losartan has shown similar effects on kidney function, including creatinine levels. Studies indicate that both drugs effectively manage blood pressure and reduce proteinuria, a marker closely related to creatinine levels and kidney health 17.
Losartan and Uric Acid Levels
Interestingly, losartan also lowers serum uric acid (SUA) levels, which has been associated with improved renal outcomes. A post hoc analysis of the RENAAL trial revealed that reductions in SUA during losartan therapy were linked to a decreased risk of renal events, including a doubling of serum creatinine . This suggests that part of losartan's renoprotective effect may be mediated through its impact on SUA levels.
Long-Term Effects and Safety
Long-term studies have shown that losartan is well-tolerated and effective in reducing creatinine levels and slowing the progression of renal disease. In a study involving hypertensive patients with chronic renal disease, losartan maintained its beneficial effects on proteinuria and creatinine clearance over an extended period, although its antiproteinuric effect slightly diminished over time 57.
Conclusion
Losartan has a significant and beneficial effect on serum creatinine levels, reducing the incidence of doubling serum creatinine and the progression to ESRD. Its renoprotective effects are comparable to other antihypertensive agents and are partly mediated through reductions in serum uric acid levels. Overall, losartan is a valuable therapeutic option for managing renal function in patients with hypertension and diabetic nephropathy.
Sources and full results
Most relevant research papers on this topic
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Losartan significantly reduces the risk of kidney damage and end-stage renal disease in patients with type 2 diabetes and nephropathy, while maintaining overall cardiovascular health.
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Aliskiren combined with losartan may have renoprotective effects in patients with hypertension, type 2 diabetes, and nephropathy, independent of its blood-pressure-lowering effect.
Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
Candesartan has the greatest reduction of proteinuria and enhancement of NOx in hypertensive patients with chronic renal disease, while losartan shows a less proteinuria-sparing and NOx-enhancing effect.
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
Losartan treatment can improve renal outcomes in proteinuric type 2 diabetic patients with the D allele of the ACE gene, despite their ACE gene polymorphism.
Randomized Placebo-Controlled Study on the Effects of Losartan and Carvedilol on Albuminuria in Renal Transplant Recipients
Losartan effectively reduces microalbuminuria in renal transplant recipients with minimal side effects compared to placebo and carvedilol.
The antiproteinuric effect of losartan is systemic blood pressure dependent.
Losartan's antiproteinuric effect is systemic blood pressure dependent, not due to a non-haemodynamic component.
DOI